SCHEMBL4290401

SCHEMBL4290401

Nc1ccc(C(=O)Nc2nccs2)c(-c2ccccc2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.61
RAB9A P51151 4/20 0.61
ALDH1A1 P00352 4/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
GAA P10253 2/20 0.61
CYP1A2 P05177 1/20 0.59
LMNA P02545 4/20 0.57
MAPT P10636 2/20 0.57
HPGD P15428 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.56
RECQL P46063 1/20 0.56
GCK P35557 1/20 0.56
MAPK8 P45983 1/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
MGAM O43451 1/20 0.52
SI P14410 1/20 0.52
MGAM2 Q2M2H8 1/20 0.52
METAP2 P50579 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4290443 0.81 NPC1 (0.60) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL4293361 0.80 NPC1 (0.62) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL4295738 0.80 NPC1 (0.66) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL27643462 0.80 GCK (0.64) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL4287851 0.78 RAB9A (0.63) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL4285959 0.77 ADORA2A (0.73) CYP1A2LMNAMAPTHPGDMEN1
SCHEMBL4286251 0.77 RAB9A (0.71) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL24074621 0.76 NPC1 (1.00) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL30339352 0.76 NPC1 (1.00) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL918766 0.76 NPC1 (0.68) NPC1RAB9AALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 NPC1 1022/4885RAB9A 2380/4885ALDH1A1 624/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 NPC1 1022/4885RAB9A 2380/4885ALDH1A1 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.